✨ Free AI Report
Anixa Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Anixa Biosciences, Inc.
Company Research

Anixa Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

Anixa Biosciences is a clinical-stage biotech company developing CAR-T immunotherapies and cancer vaccines. The company is engineering patient immune cells to fight cancer and developing a revolutionary vaccine target...

Analyst-debate audio for Anixa Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for Anixa Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Strong Buy consensus from analysts with $9.0 twelve-month price target representing 219% upside, driven by encouraging clinical...

Read the full analyst-debate transcript →
Industry Biotechnology - Oncology Therapeutics & Vaccines
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Anixa Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Anixa Biosciences, Inc. Overview

Pro stress-test →

Anixa Biosciences is a clinical-stage biotech company developing CAR-T immunotherapies and cancer vaccines. The company is engineering patient immune cells to fight cancer and developing a revolutionary vaccine targeting breast cancer, with expansion into ovarian and other solid tumors.

Strategic Profile

Pro stress-test →

Anixa leverages partnerships with world-renowned research institutions like Moffitt Cancer Center and Cleveland Clinic to advance its programs, creating a capital-efficient development model. The company focuses on addressing critical unmet needs in oncology through novel mechanisms using "retired" protein targets that differentiate it in the competitive immunotherapy space.

Competitive Landscape

Pro stress-test →

Anixa competes in the CAR-T immunotherapy and cancer vaccine space against major players like Juno Therapeutics (Celgene), Novartis, and emerging biotech firms. Its differentiation lies in the novel CER-T platform using natural hormone ligands and proprietary retired-protein vaccine technology. The company's institutional partnership model provides clinical credibility while maintaining capital efficiency relative to fully-integrated competitors.

Industry Context

Anixa Biosciences, Inc. operates in Biotechnology - Oncology Therapeutics & Vaccines.

Key facts

Founded: 1982 · Headquarters: San Jose, California · Employees: 4

What the analysts stress-tested

The top findings that survived the multi-agent debate for Anixa Biosciences, Inc..

  • Achieved ovarian cancer CAR-T dose escalation approval following Phase 1 data showing multiple patients with substantially extended survival and no dose-limiting toxicities (February 2026).
  • Breast cancer vaccine Phase 1 data demonstrates 100% immune response rate with 75% of women showing robust protocol-defined response.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Ovarian cancer CAR-T trial cleared for major dose escalation with encouraging patient survival outcomes
  • 2025Breast cancer vaccine IND transfer completed to Anixa from Cleveland Clinic
  • +1 moreTrack every material event for Anixa Biosciences, Inc. as it happens. Explore monitoring →
Get alerted when Anixa Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell TherapyLeading CAR-T developer with marketed therapies and broader oncology franchise→CAR-T Cell TherapyEstablished CAR-T player with approved therapies and extensive clinical pipeline→Cancer VaccinesDeveloping personalized neoantigen cancer vaccines with regulatory approvals→

Compare Anixa Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Anixa Biosciences, Inc. operates in Biotechnology - Oncology Therapeutics & Vaccines. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Oncology Therapeutics & Vaccines research →
NEW · MCP server

Ask your AI assistant about Anixa Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Anixa Biosciences, Inc. and its top competitor on Cyborg Score”
“What did Anixa Biosciences, Inc. do this quarter?”
“Is Anixa Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Anixa Biosciences, Inc. do?+
Anixa Biosciences is a clinical-stage biotech company developing CAR-T immunotherapies and cancer vaccines. The company is engineering patient immune cells to fight cancer and developing a revolutionary vaccine target...
What is Anixa Biosciences, Inc.'s Cyborg Score?+
Anixa Biosciences, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Anixa Biosciences, Inc.'s main competitors?+
Named competitors include CAR-T Cell Therapy, CAR-T Cell Therapy, Cancer Vaccines. The full competitive landscape is in the AskCyborg report.
How can I get the full Anixa Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Anixa Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Anixa Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.